El objetivo principal es un episodio compuesto renal definido por una disminucin del FGe50%, insuficiencia renal terminal y muerte de causa renal o muerte de causa cardiovascular, y cuya finalizacin se prev en 2024
In the 72-week SURMOUNT-5 obesity trial, tirzepatide produced an average body-weight reduction of 20.2%, compared with 13.7% for semaglutide
Evening Dosing: What the Evidence Shows Clinical trials of semaglutide and tirzepatide did not find statistically significant differences in weight loss between morning and evening injection times in healthy subjects
Oxidative stressinduced mitochondrial dysfunction drives inflammation and airway smooth muscle remodeling in patients with chronic obstructive pulmonary disease
As a rheumatologist with years of experience treating patients with autoimmune conditions, Ive seen firsthand the challenges that come with managing diseases like rheumatoid arthritis (RA), psoriasis, and psoriatic arthritis (PsA)